ProCE Banner Activity

CE

Strategies to Assist Patients With Treatment Decision Making and Managing Adverse Events of Multiple Myeloma

Multimedia
In this archived CE-certified webcast of a live meeting workshop, Beth Faiman, PhD, MSN, APRN-BC, AOCN, presents optimal nursing strategies for the management of patients with multiple myeloma.
Registered Nurses : 1.00 Nursing contact {hour}

Released: January 06, 2020

Expiration: January 05, 2021

No longer available for credit.

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Joseph D. Tariman

Joseph D. Tariman, PhC, MN, APRN, BC, OCN

Predoctoral Fellow, Dept. of Biobehavioral Nursing and Health Systems
Fellow, Achievement Rewards for College Scientists (ARCS) Foundation
School of Nursing
University of Washington
Seattle, Washington

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Celgene

Target Audience

This program is intended for oncology nurses and other healthcare providers who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Provide patient-focused education on the available clinical data and new therapeutic options for the individualized treatment of MM
  • Discuss with patients the available data and rationale for using monoclonal antibodies as well as new-generation immunomodulatory agents and proteasome inhibitors for individual patients with MM
  • Evaluate individualized treatment strategies for elderly patients through consideration of the available clinical data as well as risk assessment, comorbidities, and patient preferences
  • Develop a proactive management plan for adverse events associated with recently approved agents and novel combinations used to treat MM
  • Manage the physical, emotional, and social challenges experienced by patients diagnosed with MM through all stages of their disease

Disclosure

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Beth Faiman, PhD, MSN, APRN-BC, AOCN, has no significant financial conflicts to disclose.

Joseph D. Tariman, PhC, MN, APRN, BC, OCN

Predoctoral Fellow, Dept. of Biobehavioral Nursing and Health Systems
Fellow, Achievement Rewards for College Scientists (ARCS) Foundation
School of Nursing
University of Washington
Seattle, Washington

Joseph D. Tariman, PhD, RN, ANP-BC, FAAN, has no significant financial conflicts to disclose.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.0 contact hour may be earned for successful completion of this activity.

Disclosure of Unlabeled Use

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 06, 2020, through January 05, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve oncology nurses’ ability to educate and optimally care for patients with multiple myeloma.